• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于西蒙两阶段设计的扩展或缩短的II期研究的统计推断。

Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.

作者信息

Zhao Junjun, Yu Menggang, Feng Xi-Ping

机构信息

Department of General Dentistry, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Road, Shanghai, 200011, P.R. China.

Department of Biostatistics & Medical Informatics, University of Wisconsin, K6/446 CSC 600 Highland Ave., Madison, Wisconsin, USA.

出版信息

BMC Med Res Methodol. 2015 Jun 7;15:48. doi: 10.1186/s12874-015-0039-5.

DOI:10.1186/s12874-015-0039-5
PMID:26048655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4535394/
Abstract

BACKGROUND

Simon's two-stage designs are popular choices for conducting phase II clinical trials, especially in the oncology trials to reduce the number of patients placed on ineffective experimental therapies. Recently Koyama and Chen (2008) discussed how to conduct proper inference for such studies because they found that inference procedures used with Simon's designs almost always ignore the actual sampling plan used. In particular, they proposed an inference method for studies when the actual second stage sample sizes differ from planned ones.

METHODS

We consider an alternative inference method based on likelihood ratio. In particular, we order permissible sample paths under Simon's two-stage designs using their corresponding conditional likelihood. In this way, we can calculate p-values using the common definition: the probability of obtaining a test statistic value at least as extreme as that observed under the null hypothesis.

RESULTS

In addition to providing inference for a couple of scenarios where Koyama and Chen's method can be difficult to apply, the resulting estimate based on our method appears to have certain advantage in terms of inference properties in many numerical simulations. It generally led to smaller biases and narrower confidence intervals while maintaining similar coverages. We also illustrated the two methods in a real data setting.

CONCLUSIONS

Inference procedures used with Simon's designs almost always ignore the actual sampling plan. Reported P-values, point estimates and confidence intervals for the response rate are not usually adjusted for the design's adaptiveness. Proper statistical inference procedures should be used.

摘要

背景

西蒙两阶段设计是进行II期临床试验的常用选择,尤其在肿瘤学试验中,可减少接受无效实验性疗法的患者数量。最近,小山和陈(2008年)讨论了如何对此类研究进行恰当的推断,因为他们发现,与西蒙设计一起使用的推断程序几乎总是忽略实际使用的抽样计划。特别是,他们针对实际第二阶段样本量与计划样本量不同的研究提出了一种推断方法。

方法

我们考虑基于似然比的另一种推断方法。具体而言,我们使用西蒙两阶段设计下相应的条件似然对允许的样本路径进行排序。通过这种方式,我们可以使用常见定义计算p值:即在原假设下获得至少与观察到的检验统计量值一样极端的值的概率。

结果

除了为小山和陈的方法可能难以应用的几种情况提供推断外,在许多数值模拟中,基于我们方法得到的估计在推断性质方面似乎具有一定优势。它通常会导致更小的偏差和更窄的置信区间,同时保持相似的覆盖率。我们还在实际数据设置中展示了这两种方法。

结论

与西蒙设计一起使用的推断程序几乎总是忽略实际抽样计划。报告的反应率的P值、点估计和置信区间通常未针对设计的适应性进行调整。应使用恰当的统计推断程序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/b7343712fc19/12874_2015_39_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/fbd6c0f04156/12874_2015_39_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/56b0e3f9e540/12874_2015_39_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/5d97fa851ba2/12874_2015_39_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/b7343712fc19/12874_2015_39_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/fbd6c0f04156/12874_2015_39_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/56b0e3f9e540/12874_2015_39_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/5d97fa851ba2/12874_2015_39_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caec/4535394/b7343712fc19/12874_2015_39_Fig4_HTML.jpg

相似文献

1
Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.基于西蒙两阶段设计的扩展或缩短的II期研究的统计推断。
BMC Med Res Methodol. 2015 Jun 7;15:48. doi: 10.1186/s12874-015-0039-5.
2
Proper inference from Simon's two-stage designs.从西蒙两阶段设计中进行正确推断。
Stat Med. 2008 Jul 20;27(16):3145-54. doi: 10.1002/sim.3123.
3
Hypothesis testing for two-stage designs with over or under enrollment.针对入组人数过多或过少的两阶段设计进行假设检验。
Stat Med. 2015 Jul 20;34(16):2417-26. doi: 10.1002/sim.6490. Epub 2015 Mar 25.
4
Optimal adaptive two-stage designs for early phase II clinical trials.早期II期临床试验的最优适应性两阶段设计。
Stat Med. 2016 Apr 15;35(8):1257-66. doi: 10.1002/sim.6794. Epub 2015 Nov 3.
5
Optimal and minimax three-stage designs for phase II oncology clinical trials.肿瘤学II期临床试验的最优和极小极大三阶段设计。
Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6.
6
Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.当II期试验偏离预先指定的西蒙两阶段设计时处理数据的方法。
Stat Med. 2008 Dec 20;27(29):6190-208. doi: 10.1002/sim.3426.
7
Optimal futility stopping boundaries for binary endpoints.最佳无效终止边界的二分类结局。
BMC Med Res Methodol. 2024 Mar 28;24(1):80. doi: 10.1186/s12874-024-02190-w.
8
Optimal adaptive two-stage designs for phase II cancer clinical trials.用于II期癌症临床试验的最优适应性两阶段设计。
Biom J. 2013 Nov;55(6):955-68. doi: 10.1002/bimj.201200220. Epub 2013 Jul 19.
9
Stochastically curtailed phase II clinical trials.随机截尾的II期临床试验。
Stat Med. 2007 Mar 30;26(7):1462-72. doi: 10.1002/sim.2653.
10
A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.基于 Simon 两阶段最优设计的新型适应性设计用于 II 期临床试验。
Contemp Clin Trials. 2012 Nov;33(6):1255-60. doi: 10.1016/j.cct.2012.07.003. Epub 2012 Jul 6.

引用本文的文献

1
Confidence Intervals for Adaptive Trial Designs I: A Methodological Review.适应性试验设计的置信区间I:方法学综述
Stat Med. 2025 Aug;44(18-19):e70174. doi: 10.1002/sim.70174.
2
Optimal futility stopping boundaries for binary endpoints.最佳无效终止边界的二分类结局。
BMC Med Res Methodol. 2024 Mar 28;24(1):80. doi: 10.1186/s12874-024-02190-w.
3
Point estimation for adaptive trial designs I: A methodological review.自适应试验设计的点估计 I:方法学综述。

本文引用的文献

1
Hypothesis testing for two-stage designs with over or under enrollment.针对入组人数过多或过少的两阶段设计进行假设检验。
Stat Med. 2015 Jul 20;34(16):2417-26. doi: 10.1002/sim.6490. Epub 2015 Mar 25.
2
What inference for two-stage phase II trials?两阶段 II 期临床试验的推断是什么?
BMC Med Res Methodol. 2012 Aug 6;12:117. doi: 10.1186/1471-2288-12-117.
3
A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.用于 II 期癌症临床试验中未计划样本量的贝叶斯方法。
Stat Med. 2023 Jan 30;42(2):122-145. doi: 10.1002/sim.9605. Epub 2022 Nov 30.
4
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately.两阶段单臂试验很少被有效地分析或充分报告。
JCO Precis Oncol. 2021 Dec 16;5. doi: 10.1200/PO.21.00276. eCollection 2021.
5
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.口腔鳞状细胞癌的新辅助术前 PD-1 抑制。
Cell Rep Med. 2021 Oct 19;2(10):100426. doi: 10.1016/j.xcrm.2021.100426.
6
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.联合免疫检查点阻断和肿瘤特异性疫苗治疗不可治愈的人乳头瘤病毒 16 型相关癌症患者:一项 2 期临床试验。
JAMA Oncol. 2019 Jan 1;5(1):67-73. doi: 10.1001/jamaoncol.2018.4051.
7
Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints.具有二元终点的适应性单臂两阶段临床试验的有效置信限
BMC Med Res Methodol. 2017 Feb 6;17(1):22. doi: 10.1186/s12874-017-0297-5.
8
Exact confidence limits for the response rate in two-stage designs with over- or under-enrollment in the second stage.两阶段设计中第二阶段过度或不足招募时的反应率的确切置信限。
Stat Methods Med Res. 2018 Apr;27(4):1045-1055. doi: 10.1177/0962280216650918. Epub 2016 Jul 7.
Clin Trials. 2012 Jun;9(3):293-302. doi: 10.1177/1740774512443429. Epub 2012 Apr 20.
4
Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.在II期临床试验中允许受试者数量具有灵活性的最优两阶段设计。
J Biopharm Stat. 2009 Jul;19(4):721-31. doi: 10.1080/10543400902964167.
5
Proper inference from Simon's two-stage designs.从西蒙两阶段设计中进行正确推断。
Stat Med. 2008 Jul 20;27(16):3145-54. doi: 10.1002/sim.3123.
6
Adaptive two-stage designs in phase II clinical trials.II期临床试验中的适应性两阶段设计。
Stat Med. 2006 Oct 15;25(19):3382-95. doi: 10.1002/sim.2501.
7
On the estimation of the binomial probability in multistage clinical trials.关于多阶段临床试验中二元概率的估计
Stat Med. 2004 Mar 30;23(6):881-96. doi: 10.1002/sim.1653.
8
Optimal flexible designs in phase II clinical trials.II期临床试验中的最优灵活设计
Stat Med. 1998 Oct 30;17(20):2301-12. doi: 10.1002/(sici)1097-0258(19981030)17:20<2301::aid-sim927>3.0.co;2-x.
9
Confidence intervals following group sequential tests.
Control Clin Trials. 1986 Mar;7(1):18-26. doi: 10.1016/0197-2456(86)90004-8.
10
The bias of the sample proportion following a group sequential phase II clinical trial.成组序贯II期临床试验后样本比例的偏倚
Stat Med. 1989 May;8(5):563-70. doi: 10.1002/sim.4780080505.